98%
921
2 minutes
20
Purpose: Skin collimation provides a sharp penumbra for electron beams, while the effect of bremsstrahlung from shielding materials is a concern. This phantom study was conducted to evaluate the safety and efficacy of a real-time variable shape rubber containing-tungsten (STR) that can be placed on a patient's skin.
Methods: Electron beam profiles were acquired with the STR placed on a water-equivalent phantom and low melting-point alloy (LMA) placed at the applicator according to commonly used procedures (field sizes: 20- and 40-mm diameters). Depth and lateral dose profiles for 6- and 12-MeV electron beams were obtained by Monte Carlo (MC) simulations and were benchmarked against film measurements. The width of the off-axis distance between 80% and 20% doses (P ) and the maximum dose were obtained from the lateral dose profiles. Bremsstrahlung emission was analyzed by MC simulations at the depth of maximum dose (R ).
Results: The depth dose profiles calculated by the MC simulations were consistently within 2% of the measurements. The P at R for 20- and 40-mm diameters were 4.0 mm vs. 7.6 mm (STR vs. LMA) and 4.5 mm vs. 9.2 mm, respectively, for the 6-MeV electron beam with 7.0-mm-thick STR, and 2.7 mm vs. 5.6 mm and 4.5 mm vs. 7.1 mm, respectively, for the 12-MeV electron beam with 12.0-mm-thick STR. A hotspot was not observed on the lateral dose profiles obtained with the STR at R . The bremsstrahlung emission under the region shielded by the STR was comparable to that obtained with the LMA, even though the STR was placed on the surface of the phantom.
Conclusions: Skin collimator with STR provided superior dosimetric characteristics and comparable bremsstrahlung emission to LMA collimator at the applicator. STR could be a new tool for the safe and efficient delivery of electron radiotherapy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035551 | PMC |
http://dx.doi.org/10.1002/acm2.13210 | DOI Listing |
J Med Chem
September 2025
Faculty of Mathematics and Natural Sciences, Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.
New treatment strategies are required to combat the spread of drug-resistant malaria. The synthesis and preclinical evaluation of novel 3-hydroxy-propanamidines (HPAs), with modifications of the phenanthrene and the 4-fluorobenzamidine moieties, has yielded several analogs exhibiting excellent in vitro growth inhibition of drug-sensitive or resistant fresh clinical isolates and culture-adapted strains. No cytotoxicity in the human HepG2 cell line was observed, demonstrating notable parasite selectivity.
View Article and Find Full Text PDFAdv Ther
September 2025
Teva Branded Pharmaceutical Products R&D LLC, West Chester, PA, USA.
Introduction: Pharmacokinetic differences between long-acting injectable antipsychotic (LAI) formulations, combined with a lack of clinical switch studies, contribute to clinician uncertainty when transitioning between LAIs. This analysis employed a population pharmacokinetic (popPK) modeling approach to characterize dosing conversions and switching strategies from intramuscular paliperidone palmitate once monthly (PP1m) to TV-46000, a long-acting subcutaneous formulation of risperidone, once monthly (q1m), with a secondary analysis of PP1m to TV-46000 every 2 months (q2m).
Methods: For PP1m and TV-46000, concentration-time profiles for paliperidone and TV-46000 total active moiety (TAM; risperidone + paliperidone) were simulated on the basis of published popPK models with virtual populations of 5000 patients.
Blood Neoplasia
November 2025
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Chronic myelomonocytic leukemia (CMML) is an aggressive hematologic neoplasm characterized by an expansion of CD123 monocytes and plasmacytoid dendritic cells (pDCs). pDC bone marrow clusters in CMML have been associated with higher rates of acute myeloid leukemia transformation. We evaluated tagraxofusp, a CD123-targeted therapy, in a phase 1/2 trial for patients with CMML.
View Article and Find Full Text PDFJHEP Rep
October 2025
Janssen Pharmaceutica NV, Beerse, Belgium.
Background & Aims: Previous studies showed that combination treatment with short interfering RNA JNJ-73763989 (JNJ-3989) ± capsid assembly modulator bersacapavir (JNJ-56136379) and nucleos(t)ide analogs (NAs) was well tolerated by patients with chronic HBV (CHB), with JNJ-3989 dose-dependent reductions in viral markers, including HBsAg. The open-label, single-arm phase IIa PENGUIN study (NCT04667104) evaluated this regimen plus pegylated interferon alpha-2a (PegIFN-α2a) in patients with virologically suppressed CHB.
Methods: Patients who were either HBeAg-positive or -negative virologically suppressed and taking NAs were included; all received JNJ-3989 ± bersacapavir for 24 weeks (some either did not start or discontinued bersacapavir as a result of protocol amendment) with PegIFN-α2a added during the final 12 weeks of treatment.
Hum Reprod Open
August 2025
Department of Molecular Cell Biology, Institute of Biochemistry, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
Study Question: What is the effect of hCG on the epigenetic profile and the expression of other molecular factors in endometrial stromal cells (ESCs)?
Summary Answer: Our findings suggest that hCG treatment alters the molecular environment of decidualized ESCs, potentially influencing implantation and immune regulation through epigenetic modifications and changes in the levels of secreted proteins and micro-ribonucleic acids (miRNAs).
What Is Known Already: Embryo implantation depends not only on the quality of the embryo but also on the receptivity of the endometrium, the specialized lining of the uterus that undergoes dynamic changes to support pregnancy. Effective communication between the maternal and fetal compartments, facilitated by molecular signals and cellular interactions, is essential for successful implantation.